Executive Summary
Mission
Next-generation targeted endocannabinoid therapeutics for neurological disorders with improved safety and efficacy.
Mechanism of Action
Leverage the power of PPARÉ£ agonist pathway to administer cannabidiol in proprietary formulation for enhanced brain penetration.
Platform
Novel natural drug product derived from cannabidiol + proprietary formulation.
Current Status
Completed preclinical in-vivo studies using CQ-001.
Strategy
Best-in-class, fast-to-market strategy leveraging Epidiolex patient safety data to conduct bioequivalence (BE) study followed by Phase IIb/III study for NDA submission.
Raising Seed
$1.5M USD for IND-Enabling studies to completion of the BE study.